Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal Benefit

Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal Benefit

The EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations in high-fibrosis patients without clear mortality advantage.
Refining ARVC Risk Stratification: Does Left Ventricular Late Gadolinium Enhancement Add Incremental Value to Clinical Risk Calculators?

Refining ARVC Risk Stratification: Does Left Ventricular Late Gadolinium Enhancement Add Incremental Value to Clinical Risk Calculators?

A multi-center study of 385 ARVC patients reveals that while Left Ventricular Late Gadolinium Enhancement (LV LGE) correlates with ventricular arrhythmias, it fails to provide incremental prognostic value beyond the established ARVC risk calculator, reinforcing the calculator's role as the primary tool for clinical decision-making.
Redefining Severity in Tricuspid Regurgitation: Why CMR-Derived Regurgitant Fraction and Liver Mapping Are the New Prognostic Gold Standards

Redefining Severity in Tricuspid Regurgitation: Why CMR-Derived Regurgitant Fraction and Liver Mapping Are the New Prognostic Gold Standards

A landmark study in Circulation reveals that CMR-quantified tricuspid regurgitant fraction (TRF) ≥20% significantly increases mortality risk, while liver extracellular volume (L-ECV) mapping provides a novel, potent biomarker for systemic congestion and right heart failure outcomes.